Compare NXST & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXST | ADPT |
|---|---|---|
| Founded | 1996 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.5B |
| IPO Year | 2002 | 2019 |
| Metric | NXST | ADPT |
|---|---|---|
| Price | $166.58 | $24.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $246.75 | $29.81 |
| AVG Volume (30 Days) | 276.7K | ★ 2.0M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | ★ 4.51% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ 8.71 | N/A |
| Revenue | ★ $4,949,000,000.00 | $276,976,000.00 |
| Revenue This Year | $57.64 | $5.94 |
| Revenue Next Year | N/A | $22.42 |
| P/E Ratio | $18.94 | ★ N/A |
| Revenue Growth | N/A | ★ 54.77 |
| 52 Week Low | $153.17 | $12.00 |
| 52 Week High | $254.30 | $30.74 |
| Indicator | NXST | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 55.01 | 43.60 |
| Support Level | $154.26 | $23.73 |
| Resistance Level | $171.53 | $26.51 |
| Average True Range (ATR) | 4.45 | 1.51 |
| MACD | 1.54 | -0.30 |
| Stochastic Oscillator | 88.90 | 14.80 |
Nexstar is the largest television station owner-operator in the United States with over 200 stations in 116 markets, reaching 220 million people. Of its 200 stations, 155 are affiliated with the four national broadcast networks: CBS, Fox, NBC, and ABC. Assuming its merger with Tegna is affirmed Nexstar's station total would exceed 259 and reach 80% of the US population. Nexstar also owns NewsNation (formerly WGN), a cable news network, 75% of the fifth national broadcaster, the CW, and a 31% stake in Food Network and Cooking Channel.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.